What is the recommended starting dose and titration schedule for rosuvastatin, including maximum dose and monitoring of liver enzymes?

Rosuvastatin Dosing

Start rosuvastatin at 5-10 mg once daily in most adults, with the option to titrate up to a maximum of 40 mg daily based on LDL-C response assessed at 4-6 weeks. 1

Starting Dose

The recommended starting dose varies by patient population:

• General adult population: 5-10 mg once daily 1
• Asian patients: Start at 5 mg once daily due to increased systemic exposure; consider risks/benefits if doses above 20 mg are needed 2, 1
• Severe renal impairment (not on hemodialysis): Start at 5 mg once daily; do not exceed 10 mg daily 2, 1
• High-intensity statin therapy: When maximal LDL-C reduction (≥50%) is desired, rosuvastatin 20-40 mg provides high-intensity therapy 3, 4

Administration

Rosuvastatin can be taken at any time of day, with or without food, due to its long half-life 5, 1. This differs from shorter-acting statins that require evening dosing.

Titration Schedule

The algorithmic approach to dose titration:

1. Baseline assessment: Measure LDL-C, ALT, AST, and CK before starting therapy 5, 6, 7

2. Initial monitoring at 4 weeks: Recheck lipid panel, ALT, AST, and CK 5, 6

   • If LDL-C goal achieved and no laboratory abnormalities: Continue current dose
   • If LDL-C goal not achieved: Increase dose (typically doubling from 5→10→20→40 mg) 6

3. Subsequent monitoring:

   • Recheck at 8 weeks after initial start, then at 3 months 5
   • Once stable: Monitor every 3-4 months in first year, then every 6 months 5
   • Annual monitoring acceptable once at goal 7

4. Maximum dose: 40 mg daily 8, 1

Dose-Response Relationship

The LDL-C lowering by dose is well-established:

• 5 mg: ~42% LDL-C reduction 9
• 10 mg: ~46-47% LDL-C reduction 1, 10
• 20 mg: ~52-55% LDL-C reduction 3, 1
• 40 mg: ~55-63% LDL-C reduction 3, 1, 11

Rosuvastatin 10 mg provides comparable LDL-C lowering to atorvastatin 20 mg, simvastatin 40 mg, or pravastatin 40 mg 1.

Liver Enzyme Monitoring

Critical monitoring parameters:

• Baseline: Measure ALT and AST before starting 5, 6, 7
• At 4-12 weeks: Recheck after initiation or dose increase 7
• Routine monitoring thereafter is NOT recommended unless clinically indicated 7, 12

Management of elevated transaminases:

• ALT/AST <3× ULN: Continue therapy, recheck in 4-6 weeks 7
• ALT/AST ≥3× ULN: Temporarily withhold medication, repeat in 2 weeks; may restart when normalized 5, 6

The incidence of clinically significant ALT elevations (>3× ULN) is approximately 0.2-0.3%, similar to other statins 8, 11. Importantly, statins can be safely used in patients with compensated liver disease, including non-alcoholic fatty liver disease 12, 13.

Special Populations

Pediatric patients with heterozygous familial hypercholesterolemia:

• Ages 8 to <10 years: 5-10 mg daily 1
• Ages ≥10 years: 5-20 mg daily 1

Pediatric patients with homozygous familial hypercholesterolemia:

• Ages ≥7 years: 20 mg daily 1

Patients with diabetes or metabolic syndrome: Consider starting with rosuvastatin 20 mg (rather than 40 mg) combined with ezetimibe to achieve significant LDL-C reduction while minimizing new-onset diabetes risk 14

Common Pitfalls

1. Over-monitoring liver enzymes: Routine serial monitoring is no longer recommended and does not prevent serious liver injury 7, 12

2. Underdosing Asian patients: While starting at 5 mg is appropriate, many Asian patients can tolerate higher doses if needed for goal attainment 2

3. Premature discontinuation: Transient CK or transaminase elevations often resolve without stopping therapy; only discontinue if CK >10× ULN or ALT/AST ≥3× ULN 5, 7

4. Ignoring renal function: Patients with severe renal impairment require dose limitation to prevent accumulation 2